Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2016 - 2025)

Perspective Therapeutics has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting $10.0 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment rose 17141.38% year-over-year to $10.0 million; the TTM figure through Dec 2025 stood at $10.4 million (up 2702.7% YoY), while the FY2025 annual figure was $10.0 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $10.0 million for Q4 2025 at Perspective Therapeutics, up from $58000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $10.0 million in Q4 2025 to a low of -$14000.0 in Q3 2024.
• Average Asset Writedowns and Impairment over 3 years is $2.6 million, with a median of $192000.0 recorded in 2023.
• Year-over-year, Asset Writedowns and Impairment slumped 82.21% in 2024 and surged 17141.38% in 2025.
• Over 3 years, Asset Writedowns and Impairment stood at $326000.0 in 2023, then tumbled by 82.21% to $58000.0 in 2024, then surged by 17141.38% to $10.0 million in 2025.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $10.0 million in Q4 2025, $58000.0 in Q4 2024, and -$14000.0 in Q3 2024.